Roger S. Mcintyre MD, FRCPC

Dr. Roger McIntyre is a Professor of Psychiatry and Pharmacology at the University of Toronto and Head of the Mood Disorders Psychopharmacology Unit at the University Health Network in Toronto, Canada. He is also Executive Director of the Brain and Cognition Discovery Foundation, founder of the Canadian Rapid Treatment Centre of Excellence (CRTCE), and CEO of Braxia Scientific Corp. His academic appointments include positions at Guangzhou Medical University, Korea University, SUNY Upstate Medical University, and the University of California, Riverside.

Dr. McIntyre is internationally recognized for his research on the phenomenology, neurobiology, and treatment of mood disorders, particularly major depressive disorder and bipolar disorder. His research focuses on developing innovative, rapid-acting psychiatric treatments, advancing psychopharmacology, and improving public health outcomes through population-based and implementation research. He has authored or co-authored more than 800 scientific articles and manuscripts and has edited or co-edited several textbooks on mood disorders.

Recognized by Clarivate Analytics as one of The World's Most Influential Scientific Minds from 2014 through 2021, Dr. McIntyre is a prominent contributor to psychiatric research, clinical practice guidelines, and medical education. He has served as lead author of the Florida Best Practice Psychotherapeutic Medication Guidelines for Adults with Major Depressive Disorder and Bipolar Disorder and international expert recommendations on ketamine and esketamine in mood disorders. He has also contributed to CANMAT guidelines for depressive and bipolar disorders and clinical practice guidelines from the Royal Australian and New Zealand College of Psychiatrists.

A highly regarded educator and international speaker, Dr. McIntyre has received multiple teaching awards from the University of Toronto's Department of Psychiatry and the Canadian Psychiatric Association/Council of Psychiatric Continuing Education Award for an outstanding continuing education activity in psychiatry. He earned his medical degree from Dalhousie University and completed his psychiatry residency and fellowship in psychiatric pharmacology at the University of Toronto.